Cyclerion Therapeutics (NASDAQ:KRSA) Coverage Initiated by Analysts at Wells Fargo & Company

Wells Fargo & Company started coverage on shares of Cyclerion Therapeutics (NASDAQ:KRSA – Free Report) in a report published on Friday morning, MarketBeat Ratings reports. The brokerage issued an overweight rating and a $44.00 target price on the stock.

Several other research firms also recently issued reports on KRSA. Guggenheim assumed coverage on shares of Cyclerion Therapeutics in a research report on Monday, September 28th. They issued a “buy” rating and a $70.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research report on Friday, July 24th. TD Cowen started coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating on the stock. Wedbush started coverage on shares of Cyclerion Therapeutics in a report on Monday, October 5th. They issued an “outperform” rating and a $44.00 target price on the stock. Finally, Wall Street Zen raised shares of Cyclerion Therapeutics to a “sell” rating in a research report on Saturday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $51.20.

View Our Latest Stock Analysis on KRSA

Cyclerion Therapeutics Stock Up 1.2%

KRSA stock opened at $31.65 on Friday. The stock’s 50-day moving average is $32.07. The company has a market cap of $1.44 billion, a PE ratio of -2.49 and a beta of 1.85. Cyclerion Therapeutics has a 1 year low of $7.19 and a 1 year high of $59.36.

Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($3.19) EPS for the quarter, beating analysts’ consensus estimates of ($50.40) by $47.21. As a group, research analysts forecast that Cyclerion Therapeutics will post -5.35 EPS for the current year.

Institutional Investors Weigh In On Cyclerion Therapeutics

Several institutional investors have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Cyclerion Therapeutics in the 2nd quarter worth approximately $57,000. Braidwell LP bought a new position in Cyclerion Therapeutics in the 2nd quarter valued at $532,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Cyclerion Therapeutics during the 2nd quarter valued at $1,013,000. Hedge funds and other institutional investors own 75.62% of the company’s stock.

Cyclerion Therapeutics Company Profile

(Get Free Report)

Cyclerion Therapeutics, Inc. was a clinical-stage biopharmaceutical company focused on developing medicines for serious central nervous system and cardiopulmonary diseases. The company’s research centered on soluble guanylate cyclase (sGC) stimulators, a class of compounds intended to regulate cellular signaling and potentially address diseases associated with impaired nitric oxide signaling. Cyclerion was formed in 2019 as a spin-off from Ironwood Pharmaceuticals. Its historical development portfolio included olinciguat, an investigational treatment studied for sickle cell disease, and praliciguat, which was evaluated for conditions including diabetic nephropathy and nonalcoholic steatohepatitis.

Featured Stories

Analyst Recommendations for Cyclerion Therapeutics (NASDAQ:KRSA)

Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.